General Information


We are a precision genetic medicine company dedicated to our mission of developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing loss. We have built a precision genetic medicine platform that incorporates a proprietary vector library consisting of variants of a small virus commonly used in gene therapy, known as adeno-associated virus, or AAV, and a novel delivery approach. We are executing on our core strategic initiatives, which include the advancement of our lead product candidate, AK-OTOF, expansion of our pipeline, and development of internal manufacturing capabilities and, ultimately, a commercial infrastructure. Our aim is to leverage our capabilities to become a fully integrated biotechnology company. 

Employees: 57
Founded: 2016
Contact Information
Address 645 Summer Street, Suite 200, Boston, MA 02210, US
Phone Number (857) 410-1818
Web Address http://www.akouos.com
View Prospectus: Akouos
Financial Information
Market Cap $552.2mil
Revenues $0 mil (last 12 months)
Net Income $-30.3 mil (last 12 months)
IPO Profile
Symbol AKUS
Exchange NASDAQ
Shares (millions): 12.5
Price range $17.00 - $17.00
Est. $ Volume $212.5 mil
Manager / Joint Managers BofA Securities/ Cowen/ Piper Sandler
CO-Managers BTIG
Expected To Trade: 6/26/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change